Cancer's DNA Instability Is Its Weakness, and New Drugs Are Exploiting It

Genomic instability is a hallmark of cancer. When the cellular machinery that preserves DNA integrity falters, genetic and epigenetic alterations accumulate and drive malignant transformation. The authors describe this as both the architect of cancer's evolution and its Achilles' heel, which matters because it is a therapeutic vulnerability that can be exploited.

This is a narrative review from Cell, written by authors at MD Anderson, AstraZeneca, and Oregon Health & Science University. It traces the history of therapies that target genomic instability. Systemic chemotherapy and external beam radiation came first. PARP inhibitors followed, particularly for tumors with homologous recombination repair deficiency, along with other DNA damage response targets.

The abstract's main conclusion is that the field has moved into a new phase. Tumor-targeted DNA-damaging platforms, specifically antibody-drug conjugates (ADCs) and radiopharmaceuticals, have emerged. They deliver DNA damage more selectively to cancer cells. They are being developed alongside precision medicine strategies intended to optimize patient selection, build rational combination regimens, and widen the therapeutic index.

For clinicians and informed readers, the review frames DNA repair biology as a unifying logic across many cancer treatments. It suggests future progress will depend on biomarkers that identify who benefits and on combinations that increase efficacy without adding unacceptable toxicity.

Caveats: only the abstract was available, so specific trial data, drug names, effect sizes, and resistance mechanisms cannot be summarized. As a review, it offers expert synthesis rather than new experimental evidence. Several authors have extensive industry ties, including to companies developing DDR drugs, ADCs, and radiopharmaceuticals, which may shape emphasis.